Background. Our goal was to determine the relationship between serum vancomycin trough concentrations (VTCs) and changes in pulmonary function among individuals with an acute pulmonary exacerbation (APE) of cystic fibrosis (CF).
Over the past decade, the prevalence of methicillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis (CF) has increased dramatically from 14.8% in 2004 to 25 .9% in 2014 [1] . In patients with CF, infection with MRSA has been associated with decreased pulmonary function, a more rapid decline in forced expiratory volume in 1 second (FEV 1 ), and an increased mortality rate [2] [3] [4] [5] [6] [7] . In addition, persistent MRSA infections have been associated with an increased use of intravenous antibiotics, an increased rate of hospitalization, and increased lengths of stay [3, 5] .
Because of these consequences, it is important to optimize the treatment of acute pulmonary exacerbations (APEs) secondary to MRSA. Although vancomycin is largely considered a first-line agent, limited data to support its use in patients with CF exist [8] [9] [10] [11] . Moreover, the 2009 CF pulmonary guidelines for the treatment of pulmonary exacerbations do not address the treatment of APEs secondary to MRSA [12] . According to adult guidelines for treating MRSA, a target area under the curve-to-minimum inhibitory concentration ratio (AUC/MIC) of ≥400:1, which corresponds to a vancomycin trough concentration (VTC) range of 15 to 20 µg/mL, is recommended for serious infections such as bacteremia, infective endocarditis, osteomyelitis, meningitis, pneumonia, and severe skin and skin-structure infections [10, 13] . On the basis of these recommendations, it might be appropriate to target this VTC range when treating MRSA infection in patients with CF; however, dosing and monitoring recommendations specific to patients with CF are lacking. In addition, extrapolating pharmacokinetic (PK) and pharmacodynamic (PD) data from adults and applying it to children might not be appropriate. Recent PK/PD data in children (≤21 years of age) receiving vancomycin in doses of 60 to 70 mg/kg per day indicate that VTCs of approximately 8 to 9 µg/mL correspond to an AUC/MIC of 400:1 [14] . Therefore, vancomycin dosing based on VTC alone in children might lead to unnecessary increases in drug exposure when adult VTC targets are applied [14] . In the absence of goal VTC data specific to CF, many institutions are following the adult MRSA-treatment guidelines. A recent survey of Cystic Fibrosis Foundation-accredited care centers found that 84% of respondents target VTCs of 15 to 20 µg/mL [11] . Targeting a higher VTC in patients with CF, however, must be balanced with the risk of toxicity. Higher VTCs (≥15 µg/mL) in children have been associated with an increased risk of developing acute kidney injury (AKI) [15] [16] [17] .
Understanding the optimal target VTC is imperative for maximizing both safety and efficacy. To our knowledge, there are no published data correlating the above-cited goal VTCs for treating MRSA infection with clinical outcomes and safety in patients with CF. Current practice at our institution is to initiate vancomycin at 10 to 15 mg/kg per dose administered every 6 to 8 hours and to target a VTC of 10 to 15 µg/mL when treating patients with CF who are infected with MRSA. The purpose of this study was to determine the relationship between VTC and improvement in pulmonary function, as measured by change in FEV 1 . Secondary objectives included describing vancomycin use characteristics, change in lung function as measured by other pulmonary function tests (PFTs), and changes in renal function.
MATERIALS AND METHODS

Study Design and Definitions
A retrospective cohort study was conducted. Patients were included if they had a positive diagnosis of CF, were ≥6 years of age (for reliable PFT results), were hospitalized for an APE of CF between May 1, 2012, and April 30, 2014, had ≥1 sputum culture test positive for MRSA within 30 days of hospital admission, received ≥48 hours of intravenous vancomycin with ≥1 appropriately measured trough concentration during the study period, and had ≥2 sets of PFTs during their admission (within 48 hours of admission and discharge, respectively). Multiple hospital admissions during the study period by patients who met inclusion criteria were included as separate encounters. A patient was excluded from the study if he or she underwent lung transplantation before or during the study period or was pregnant at the time of admission. The study was approved by the University at Buffalo Institutional Review Board.
Demographic data that were collected included age, sex, height, weight, admission and discharge dates, and adjuvant therapies during the encounter. Vancomycin dose, frequency, duration, initial and postdose adjusted (final) VTCs, and associated dosing administration times and trough concentration measurement times were collected. A VTC was considered to be drawn appropriately if it was drawn within 30 minutes of the true trough (ie, within 30 minutes of the 8-hour mark for every 8-hour dosing regimen). The final VTC was considered to be the trough after which time no vancomycin dose adjustments were made. Data on concomitant antimicrobial agents and systemic nephrotoxic agents (eg, aminoglycosides, contrast dye, amphotericin, colistin, and ibuprofen) during vancomycin treatment were collected. Vancomycin clearance (L/h) was calculated using the model by Le et al [14] . The AUC was calculated as total daily vancomycin dose (mg/day) divided by vancomycin clearance. AUC/MIC ratios were determined by the 24-hour AUC divided by the MIC. The MIC of the MRSA isolate obtained closest to hospitalization was used.
Admission and discharge FEV 1 , forced vital capacity (FVC), and average forced expiratory flow during the midportion of the FVC (forced expiratory flow between 25% and 75% of expired FVC [FEF ]) were collected. Return to baseline lung function (based on FEV 1 ) was defined as a follow-up FEV 1 that was ≥90% of the baseline FEV 1 . Baseline FEV 1 was defined as the maximum FEV 1 recorded in the patient's medical record in the 6 months before the index hospitalization, and follow-up FEV 1 was defined as the highest FEV 1 measured within 24 hours of hospital discharge up to 4 weeks after discharge. This follow-up time period was chosen to account for the variability in FEV 1 measurements and is consistent with that in other studies [7] . Sputum culture data during and within 6 months of the hospitalization were collected; these data included the bacterial pathogen(s) identified, the MIC of the MRSA species, the date of the positive culture results, and the qualitative description of MRSA density (reported by the microbiology laboratory as "few, " "moderate, " or "many"). Data regarding outpatient antibiotic treatment before hospital admission, including drug name, dose, and duration, were collected also. Serum creatinine (SCr) values were recorded, and AKI was defined as an increase in the SCr level of ≥0.3 mg/dL within 48 hours, an increase in the SCr level to 1.5 times baseline within 7 days, or a urine volume of ≤0.5 mL/kg per hour for 6 hours [18] .
Statistical Analyses
Data were summarized using descriptive and inferential statistics. Means ± the standard deviation were used to describe continuous data. Frequencies and percentages were used to describe discrete variables. Data were assessed for normality by visual inspection of histograms and through the KolmogorovSmirnov test. Nonnormally distributed data were transformed with log or reciprocal functions. Changes in lung function parameters between admission and discharge were analyzed with paired t tests. Pearson correlations were performed to characterize the bivariate relationship between dependent and independent variables. Linear models were developed for dependent parameters, including percentage changes in FEV 1 , FVC, FEF , length of hospital stay, and time to readmission. Models were fit using individual predictor variables of vancomycin exposure, including trough serum concentration (continuous and categorical variable bins, 5 to <10 µg/mL, 10 to <15 µg/mL, 15 to <20 µg/mL, and ≥20 µg/mL), weight-adjusted daily dose (mg/kg per day), and AUC/MIC (continuous and categorical variables with a breakpoint of 400:1). Additional predictor variables included admission lung function, concomitant use of aminoglycosides, use of broad-spectrum antibacterial agents, Pseudomonas aeruginosa infection, sputum MRSA density, outpatient antibiotics before admission, sex, age, and weight. Categorical variables were used for weight: underweight (body mass index [BMI] of <5th percentile for children [≤20 years old] or <18.5 for adults [>20 years old]), healthy weight (BMI of 5th-85th percentile for children or 18.5 to <25 for adults), and overweight (BMI of >85th percentile for children or ≥25 for adults). Model fit was assessed through diagnostic plots and r 2 values. All tests were 2-tailed with α set at 0.05. Statistical analysis was completed using SAS 9.4 (SAS Institute, Inc, Cary, NC).
RESULTS
A total of 243 patient encounters were identified, 194 of which did not meet inclusion criteria. Of the excluded patients, 170 did not have a diagnosis of CF, 11 did not receive ≥48 hours of vancomycin, 5 had no record of MRSA infection in the sputum, 5 lacked PFT data at the time of admission or discharge, 2 had admission for a reason other than an APE, and 1 had an incomplete electronic medical record. Patient demographic characteristics for the 49 patients who met inclusion criteria are summarized in Table 1 . The mean age of the patients was 17 years; 10 (20.4%) patients were aged 6 to 12 years, 30 (61.2%) were aged 13 to 21 years, and 9 (18.4%) were aged ≥21 years.
Vancomycin PK and PD data are summarized in Table 2 . Of the 49 patient encounters, 35 (71.4%) required a vancomycin dose adjustment before achieving their final VTC. It was notable that 2 VTCs in the 15 to <20 µg/mL range were 15.0 and 15.2 µg/mL, and 4 VTCs in the 5 to <10 µg/mL range were >9 µg/ mL. Concomitant antimicrobial agents that were used included an aminoglycoside (49%), cefepime (36.7%), rifampin (30.6%), piperacillin-tazobactam (18.4%), a fluoroquinolone (16.3%), and a carbapenem (10.2%). No patient received colistin. One (2%) patient (83 kg) was exposed to ibuprofen (600 mg twice daily) for 3 days during vancomycin treatment. Vancomycin PK data for the 3 age strata listed above are summarized in Table 3 .
The admission and discharge PFT data are summarized in Table 4 . A total of 42 (85.7%) patients returned to their baseline FEV 1 . There was no difference in VTCs between patients who returned to their baseline FEV 1 (12.6 ± 3.6) and those who did not (12.8 ± 1.5) (P = .599). There was no correlation observed between VTC and percent change in FEV 1 (Pearson r = −0.10; P = .49) (Figure 1) , FVC (r = −0.10; P = .476), or FEF (r = −0.17; P = .261). In addition, there was no correlation between VTC and time to readmission (r = 0.21; P = .153) or hospital length of stay (r = 0.02; P = .901).
Results of the multivariable linear regression for pulmonary function outcomes are displayed in Table 5 . The regression selected for each variable represents a parsimonious and statistically significant model. Among the dependent variables, younger age and lower admission lung function were significant predictors for a positive response. VTC was not a significant predictor for lung function response variables. The AUC/MIC (P = .21), sputum MRSA density (P = .43), and treatment with outpatient antibiotics before admission (P = .52) did not have an association with percent change in FEV 1 or any of the dependent variables. Change in FEV 1 (23.7% ± 25.4% vs 26.9% ± 21.9%; P = .69), VTC (12.6 ± 3.7 μg/mL vs 12.8 ± 1.7 μg/mL; P = .74), and return to baseline FEV 1 [33 (89.2%) vs 9 (75%); P = .34] did not differ between patients who achieved an AUC/MIC of <400:1 (n = 37) or ≥400:1 (n = 12). Achieving an AUC/MIC of ≥400:1 did not have did not have an association with any of the other dependent variables. One (2%) case of AKI was identified when a rise in the SCr level from 0.71 to 2.26 mg/dL occurred over a period of 5 days. During this time, the vancomycin dose was increased from 20 mg/kg per dose every 12 hours (VTC = 7.8 µg/mL) to 20 mg/kg per dose every 6 hours (VTC = 8.1 µg/mL). The patient remained on this dose for 48 hours, at which point the SCr level increased to 2.26 mg/dL. A repeat VTC at this time was 30.9 µg/mL, and vancomycin was held for 3 days. During this time, the patient also was exposed to tobramycin (10 mg/kg per dose = 800 mg intravenously daily) and ibuprofen (600 mg twice daily for 3 days). The patient's tobramycin levels were measured on the same day that the SCr level had increased to 2.26 mg/dL and were found to 14.4 µg/mL (2-hour level) and 1.5 µg/mL (10-hour level), which correlated to a true peak of 19.1 µg/mL (extrapolated 18-hour level, 0.16 µg/mL) and an AUC of 82.8 mg·h/L, both of which were within acceptable limits. Vancomycin treatment was restarted when the VTC decreased to 16.8 µg/mL, at which time the SCr level also returned to a baseline of 0.73 mg/dL.
DISCUSSION
To our knowledge, this is the first study to have specifically examined the relationship between VTCs and changes in pulmonary function in people with APEs of CF and a sputum culture positive for MRSA. The majority of patients in this study experienced improvement in their lung function, as indicated by 85.7% of them returning to their baseline FEV 1 value while achieving VTCs in the range of 10 to <15 µg/ml (81.6%). The mean AUC/MIC was 338.65 ± 123.3, which is below the recommended target of 400:1 for treating serious invasive MRSA infections [10, 13] . However, all patients in this study had significant improvement in their PFT results and experienced resolution of their APE of CF to the point that they all were discharged from the hospital. Although this data set is limited by a small sample size, our results suggest that a lower vancomycin trough target of 10 to 15 µg/ml might be an acceptable alternative to the current 15 to 20 µg/ml target in patients with APE of The P values were determined from paired t tests comparing admission and discharge values. CF. Larger studies with a wider distribution of trough values are necessary to further define the optimal target. We were unable to identify a correlation between markers of vancomycin exposure, including VTCs and AUC/MIC, and change in PFT results or return to baseline FEV 1 . The multivariate regression models also revealed no relationship but did reveal important patient characteristics indicative of response. PFT results on admission and age were inversely associated with response. Because CF is a progressive disease, it is expected that younger patients have less advanced lung disease and therefore might experience a more robust response to treatment. Similarly, those patients with lower admission pulmonary function might experience a greater change in PFT values between admission and discharge.
Data regarding vancomycin use in patients with CF have suggested a lack of correlation between initial vancomycin dose (45-100 mg/kg per day) and both the final vancomycin dosage regimen and VTCs [19, 20] . Fung [20] described 3 pediatric patients (aged 3, 5, and 17 years) who failed to achieve VTCs of >15 µg/mL on a vancomycin dose of 60 to 70 mg/kg per day divided every 6 hours. These patients were converted to a continuous infusion of vancomycin (31-50 mg/kg per day). All 3 patients improved clinically, but only 2 of them achieved an AUC/MIC of >400:1. McDade et al [21] reported that despite vancomycin dose adjustments, 58% of treatment courses (n = 90) never achieved the goal VTC of 15 to 20 µg/mL. For their secondary outcome, they did not find a difference in the change in FEV 1 between treatment courses that achieved the goal VTC (n = 4; 14.5% ± 12.6%) and those that did not (n = 45; 13.4% ± 12.6%). These data are consistent with the data from our study, in which 82% of VTCs were within the range of 10 to <15 µg/ml, the change in FEV 1 was 24.5% ± 24.4%, and achievement of VTCs of 15 to 20 µg/mL did not seem to predict or change clinical outcomes as defined by changes in PFT results. Recent PK/PD data from children (≤21 years of age) indicate that an AUC/MIC of 400:1 corresponds to a VTC of approximately 8 to 9 µg/mL for regimens of 60 to 70 mg/kg per day [14] . In our study, the majority (n = 37) of the patients achieved an AUC/ MIC of <400:1 while achieving a corresponding mean VTC of 12.6 ± 3.7 µg/mL while on a similar dose of vancomycin. It is important to note that failure to achieve an AUC/MIC of ≥400:1 in our study was likely driven by a higher mean MRSA MIC (1.8 ± 0.27 mg/L). However, we found no difference in change in FEV 1 , VTCs, or return to baseline FEV 1 in those patients who achieved an AUC/MIC of <400:1 versus those whose AUC/ MIC was ≥400:1. This study was not designed to specifically evaluate PK differences in patients with CF; however, these data are consistent with those of previous studies that described the use of vancomycin in children with CF as challenging and unpredictable when based on PK targets alone.
Several studies have identified risk factors for developing AKI in patients treated with vancomycin [15] [16] [17] [22] [23] [24] . These risk factors include higher (≥15 µg/mL) VTCs, higher vancomycin doses, longer durations of treatment, and concomitant administration of other nephrotoxic drugs [15] [16] [17] [22] [23] [24] , risk factors that are common in patients with CF, who are known to receive repeated aminoglycoside and/or vancomycin treatment courses over their lifetime. A single case of AKI was identified among this cohort of patients who had, in general, lower average vancomycin exposure (53.9 ± 17.6 mg/kg per day) compared to usual vancomycin doses of 60 to 70 mg/kg per day. This patient had multiple risks for nephrotoxicity, which reinforces that the use of chronic therapies such as ibuprofen in the setting of aminoglycoside and vancomycin should be avoided because of the increased risk of nephrotoxicity [12, 25] .
There are several limitations to this study. This was a retrospective medical chart review with a small number of included subjects within a single CF center, which introduces the risk of a type II error. There was low variability in the observed VTCs (12.6 ± 3.33 µg/mL); thus, it was difficult to establish a relationship between VTC and changes in pulmonary function. One major assumption that we made during the study was that MRSA was the cause of the APE; however, patients with CF can be colonized or infected with other microorganisms that can also contribute to an APE [1] . To mitigate this limitation, we excluded patients from whom MRSA in sputum was not isolated. Adjunctive nonantibiotic treatments (eg, chest physiotherapy, hypertonic saline, dornase alfa, and short-acting β agonists) can also lead to clinical improvement during an APE. Patients in our study received similar adjunctive therapies as recommended by the Cystic Fibrosis Foundation guidelines. Vancomycin PK and PD were calculated on the basis of the model by Le et al [14] , which was created from a heterogeneous population of children. However, this model was validated recently in a study that included children with CF [26] . Limited data regarding vancomycin PK and PD exist for children with CF. Vancomycin PK and PD parameters were also calculated on the basis of a second model by Le et al [27] and a model by Stockmann et al [28] , which did include people with CF. All parameters were within a 10% error, which suggests a precise and robust estimate based on the model by Le et al [14] .
CONCLUSIONS
A study of patients with CF hospitalized for treatment of an APE with vancomycin revealed that the majority of them experienced improvement in pulmonary function and a return to their baseline FEV 1 (85.7%) while achieving VTCs in the range of 10 to <15 µg/mL (81.6%). We were unable to identify a correlation between markers of vancomycin exposure, including VTCs and AUC/MIC, and change in PFT results. Although this was a retrospective study and we cannot infer causality from the observed associations, the approach to achieving a VTC in the range of 10 to 15 µg/ml was a successful strategy associated with clinical improvement. Given these positive outcomes and risk factors for AKI to which patients with CF are exposed, future research should evaluate the optimal VTC goal (ie, 10-15 vs 15-20 µg/ml) when treating MRSA infection in patients with CF.
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